ClinicalTrials.gg
Not yet recruitingNCT07888088Updated Oct 22, 2026

Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults

A Phase 1 interventional study of MVA-BN-EBV and Placebo in Epstein Barr Virus (EBV) Infection, sponsored by Bavarian Nordic. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Bavarian Nordic · Phase 1, Interventional, and Treatment

Updated Oct 22, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 76 studies in Epstein-Barr Virus Infections with a site in United States — 19 open to participants now, 25 under way, 2 of them phase 3. Epstein-Barr Virus Infections · United States.

Planned enrollment
44th of 63
15 · median 25
Started
2026
with 1 other
Phase 1
19 of 76
8 open now
Primary completion
2027-12
later than 10 of 23 live
Registered
76th of 76
by date

Among the 76 studies in Epstein-Barr Virus Infections with a site in United States, this one is the 44th largest by planned enrollment of the 63 interventional ones that give a count, is one of 2 that started in 2026, is one of 19 in phase 1, reaches primary completion later than 10 of the 23 other live ones, and was the 76th registered.

Epstein-Barr Virus Infections

175 studies on the registry are indexed under Epstein-Barr Virus Infections; 60 are open to participants now.

Browse Epstein-Barr Virus Infections studies →

Open to participants now

19 of the 76 studies in Epstein-Barr Virus Infections with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Epstein-Barr Virus Infections studies recruiting now, 23 (53%) set no upper age limit and 16 (37%) stop at 75 or younger; 23 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Epstein-Barr Virus Infections with a site in United States, or all of them as a file.
02

Study summary

Phase 1, single-center, randomized, placebo-controlled, double-blind clinical trial.

Participants (N = 15) will receive a 2-dose schedule (1 vaccination on day 1 and day 28) randomized, receiving either MVA-BN-EBV (n = 12) or placebo (n = 3).

Read the detailed description

Phase 1, single-center, randomized, placebo-controlled, double-blind clinical trial.

Participants (N = 15) will receive a 2-dose schedule (1 vaccination on day 1 and day 28) randomized, receiving either MVA-BN-EBV (n = 12) or placebo (n = 3).

Recruitment into the trial will be performed in a staggered approach. In each cohort, participants will be randomized to receive either MVA-BN-EBV or placebo. The trial will start with a sentinel cohort of 2 participants, 1 receiving the MVA-BN-EBV vaccine and the other receiving the placebo.

03

Conditions studied

  • Epstein Barr Virus (EBV) Infection

Keywords

  • phase 1 study, healthy volunteer
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 and ≤30 years at screening
  2. form (ICF) signed and dated by the participant after reading the form and being advised of the risks and benefits of the trial in a language understood by the participant and before performance of any trial-specific procedures
  3. General good health, without any medical illness, physical exam findings, or laboratory abnormalities, as determined by the PI
  4. (BMI) ≥18.5 and ≤35.0

    • BMI formula for kilograms and meters (round to 1 decimal place): BMI = (body weight in kilograms) / (body height in meters)\^2
    • BMI formula for pounds and inches (round to 1 decimal place): BMI = (body weight in pounds) × 703 / (body height in inches)\^2
  5. Assertion by participant that one of the following regarding avoidance of pregnancy is true:

    1. Female participant or female partner(s) of male participant is at least 1 year (amenorrhea >12 consecutive months in the absence of other pathologic or physiologic causes, following cessation of exogenous sex-hormonal treatment, and documented FSH level of ≥40 mIU/mL) at screening
    2. Participant and/or participant's partner(s) is surgically sterile (bilateral oophorectomy, bilateral salpingectomy, hysterectomy, confirmed hysteroscopic sterilization, such as Essure®, vasectomy)
    3. Female participant of or male participant who is sexually active with a female partner of childbearing potential agrees to use a highly effective method of from at least 30 days prior to administration of vaccine until 60 days after last vaccination; medically acceptable methods of contraception that may be used by the participant and/or partner include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS) , bilateral tubal ligation, or true abstinence (abstinence only acceptable if refraining from heterosexual intercourse during the entire period of 30 days prior to administration of vaccine until 60 days after last vaccination). Periodic abstinence (such as calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    4. Participant is in an exclusively same-sex relationship. These participants should not have plans to become pregnant by any other means for at least 60 days after IMP administration.
  6. No plans to become pregnant by intrauterine insemination or in vitro fertilization, to harvest eggs, or to donate or bank sperm through 60 days after last vaccination.
  7. Negative antibody test (anti-HIV), negative surface antigen (HBsAG), and negative antibody test to virus (HCV)
  8. Willingness to comply with the requirements of the protocol, in the judgment of the investigator

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or breast-feeding
  2. Any condition that, in the opinion of the investigator, creates an unacceptable risk to the participant
  3. Any condition that, in the opinion of the investigator, will interfere with the conduct of the trial or the validity of the data.
  4. Acute or chronic medical condition that, in the opinion of the PI, would render the trial procedures unsafe or would interfere with the evaluation of the responses, including but not limited to, neurologic, cardiovascular, respiratory, hepatic, hematologic, rheumatologic, endocrine, gastrointestinal, renal, , or conditions
  5. History of, or active autoimmune disease (vitiligo or thyroid disease requiring thyroid replacement are not exclusions), such as history of Guillain-Barré syndrome or Reye's syndrome
  6. Known immunodeficiency syndrome or known or suspected impairment of immunologic functions including, but not limited to, liver disease, diabetes mellitus type I, or moderate to severe kidney impairment
  7. Known or suspected previous smallpox/mpox vaccination or vaccination with any licensed or poxvirus-based vaccine
  8. History of monkeypox, cowpox, or vaccinia infection
  9. Close contact with anyone known to have mpox in the 3 weeks prior to signing ICF
  10. History of other than squamous cell or basal cell skin cancer, unless there has been surgical excision at least 6 months prior to screening that is considered to have achieved cure. Participants with history of skin cancer must not be vaccinated at the previous tumor site.
  11. Clinically significant mental disorder not adequately controlled by medical treatment
  12. Active or recent (within 6 months before screening) evidence of substance abuse (eg, chronic alcohol abuse and/or intravenous and/or nasal drug abuse) that, in the opinion of the investigator, could adversely impact the participant's participation or the conduct of the study
  13. History of known or suspected allergic disease or reaction likely to be exacerbated by any component of the vaccine, eg, tris(hydroxymethyl)-amino methane, quail proteins.
  14. History of anaphylaxis or severe allergic reaction to any vaccine
  15. Receipt of or plans to receive any licensed from 30 days prior to first trial vaccination until 30 days after last trial vaccination
  16. Receipt of or plans to receive any licensed non live vaccine from 14 days prior to first trial vaccination until 14 days after last trial vaccination
  17. Use of any investigational or nonregistered agent within 30 days prior to trial vaccination or plans to receive an investigational agent during the trial until 6 months after last trial vaccination
  18. Recent blood donation (including , plasma, and red blood cells) within 4 weeks prior to screening and or planned blood donations through the EAP
  19. Use of systemic administration or any other immune modifying drugs defined as use at a dose or equivalent dose of 20 mg of prednisone daily for 14 days or more from 3 months prior to the first trial vaccination to the EAP visit. The use of inhaled, intranasal, topical, ocular, or intraocular steroids is allowed
  20. History of organ transplantation, whether or not chronic immunosuppressive therapy is being administered
  21. Administration or planned administration of immunoglobulins (with an exception for monoclonal antibodies for treatment of migraines) and/or any blood products from 3 months prior to the first trial vaccination until the EAP visit (packed red blood cells given for an emergency indication in an otherwise healthy person and not required as ongoing treatment is not exclusionary [eg, packed red blood cells given in an emergency during elective surgery])
  22. History of coronary heart disease, myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or , uncontrolled high blood pressure, significant arrhythmia with or without corrective/ablative surgery, abnormal troponin I level > (ULN), or any other heart condition under the care of a doctor
  23. Employment with the PI or CTS, with direct involvement in the proposed study or other studies under the direction of that PI or CTS, or relationship to the PI or CTS employee
  24. Relationship with Bavarian Nordic as an employee or employee family member, contractor, agent, or business partner, or having a financial interest in the outcome of the trial
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
15 participants (estimated)

Study arms

  • Active comparator
    MVA-BN-EBV

    Liquid frozen suspension of MVA-BN-EBV vaccine (distributed in single dose vials) will contain at least 3 × 108 Inf.U per 0.5 mL. MVA-BN-EBV vaccine will be given by intramuscular (IM) administration into the deltoid of the upper arm (preferably the non-dominant arm). Each participant will receive 2 vaccinations, 28 days apart.

    Biological: MVA-BN-EBV

  • Placebo comparator
    Placebo

    One dose of 0.5 mL placebo contains 0.605 mg trometamol (tris-hydroxymethyl-amino methane) and 4.09 mg sodium chloride (TBS). It is administered as an IM injection into the deltoid of the upper arm (preferably the non-dominant arm). Each participant will receive 2 vaccinations, 28 days apart.

    Biological: Placebo

Interventions

  • BiologicalMVA-BN-EBV

    MVA-BN-EBV

  • BiologicalPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Number of participants with Serious Adverse Events (SAEs)

    Any postvaccination SAE, regardless of relationship to trial vaccine, throughout the trial

    Time frame: From first vaccination through Week 8

  2. Number of participants with a grade 3 or higher AEs assessed as related to trial vaccine

    Any grade 3 or higher AEs assessed as related to trial vaccine through the EAP

    Time frame: The day of or within 8 days after either vaccination

  3. Number of participants with any solicited local and/or systemic AEs for an 8 day period

    Any solicited local and/or systemic AEs for an 8-day period (day of vaccination plus 7 days)

    Time frame: The day of or within 8 days after either vaccination

  4. Number of participants with any postvaccination MAAEs

    Any postvaccination MAAEs, regardless of relationship to trial vaccine, throughout the trial

    Time frame: From first vaccination through the end of the trial at Week 32 (v5)

  5. Number of participants with any postvaccination AESI

    Any postvaccination AESI, regardless of relationship to trial vaccine, throughout the trial

    Time frame: From first vaccination through the end of the trial at Week 32 (v5)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2026
First posted
Oct 22, 2026
StartEst.
Dec 15, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07888088
Lead sponsor
Bavarian Nordic
Responsible party
Sponsor
First posted
Oct 22, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Bavarian Nordic A/S, MD
Contact
medical.information@bavarian-nordic.com
844-422-8274

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion